NLRP3 and ulcerative colitis: In another study, it was found that HTyr (40 mg/kg/day orally for 14 days) exerted anti-inflammatory activity in murine DSS-induced ulcerative colitis by inhibiting NLRP3 inflammasome activation, through the suppression of the expression levels of NLRP3, caspase-1 and the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) mRNA, thus decreasing IL-18 and IL-1β levels.